05:32 PM EDT, 05/23/2024 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) said late Thursday that combination therapy of GN7075 and Libtayo, or cemiplimab, led to anti-tumor responses in patients with microsatellite stable colorectal cancer based on data from the dose-escalation portion of an ongoing phase 1/2 trial.

Efficacy results from 51 patients with microsatellite stable colorectal cancer showed a 6% overall response rate and a 29% disease control rate, the drugmaker said.

"Microsatellite stable colorectal cancer has historically been unresponsive to immunotherapy" but the combination therapy showed "anti-tumor responses in a highly difficult-to-treat cancer," according to a trial investigator.

Safety was evaluated in 84 patients across multiple solid tumor types at various doses of REGN7075. Treatment-emergent adverse events of any grade occurred in 98% of patients, while treatment-related adverse events occurred in 90% of patients, the company said.

Price: 982.72, Change: +2.15, Percent Change: +0.22